Carbohydrate Research 401 (2015) 11-15

Contents lists available at ScienceDirect

Carbohydrate Research

journal homepage: www.elsevier.com/locate/carres

Structure of the O-polysaccharide of *Providencia alcalifaciens* O2 containing ascarylose and *N*-(L-alanyl)-D-glucosamine



Olga G. Ovchinnikova^{a,†}, Magdalena Moryl^b, Alexander S. Shashkov^a, Alexander O. Chizhov^a, Nikolay P. Arbatsky^a, Anna M. Shpirt^a, Antoni Rozalski^b, Yuriy A. Knirel^{a,*}

^a N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russian Federation ^b Department of Immunobiology of Bacteria, Institute of Microbiology, Biotechnology and Immunology, University of Lodz, PL 90-237 Lodz, Poland

ARTICLE INFO

Article history: Received 29 August 2014 Received in revised form 17 October 2014 Accepted 20 October 2014 Available online 27 October 2014

Keywords: Providencia alcalifaciens O-Antigen Lipopolysaccharide Bacterial polysaccharide structure Ascarylose

ABSTRACT

The O-polysaccharide was obtained by degradation of the lipopolysaccharide of *Providencia alcalifaciens* O2 under mild acidic conditions followed by GPC. The polysaccharide was found to contain two unusual components: 3,6-dideoxy-L-*arabino*-hexose (ascarylose, Asc) and 2-(L-alanyl)amino-2-deoxy-D-glucose (GlcNAla). Ascarylose was partially split off during lipopolysaccharide degradation and could be eliminated completely by selective acid hydrolysis, which also partially cleaved the β -GalNAc-(1 \rightarrow 6) linkage. The following structure of the branched pentasaccharide repeating unit was established by ¹H and ¹³C NMR spectroscopy of the O-polysaccharide and O-deacetylated polysaccharide, as well as products of partial acid hydrolysis:

 $\begin{array}{c} \begin{array}{c} \alpha - Ascp - (1 \rightarrow 4) - \alpha - D - GlcpA - (1 \rightarrow 4) \\ \rightarrow & - \beta - \beta - D - GlcpNAla - (1 \rightarrow 4) - \beta - D - GlcpA - (1 \rightarrow 3) - \beta - D - GalpNAc - (1 \rightarrow 4) \\ - & - \alpha 0 \% OAc - 3) \end{array}$

© 2014 Elsevier Ltd. All rights reserved.

Bacteria of the genus *Providencia* are widespread in nature and may cause urinary tract infections and enteric diseases in humans.¹ A combined O-antigen (O-polysaccharide)-based serotyping scheme for medically important *Providencia* species, *Providencia alcalifaciens*, *Providencia stuartii* and *Providencia rustigianii*, consists of 63 O-serogroups.² Aiming at elaboration of the chemical basis for this classification, O-polysaccharide structures have been established for 38 O-serogroups.^{3–5} In this work, we elucidated the structure of the O-polysaccharide of the lipopolysaccharide (LPS) of *P. alcalifaciens* O2.

The LPS was isolated from bacterial cells by the phenol–water procedure⁶ and degraded with aq 2% acetic acid. Fractionation of the carbohydrate portion by GPC on Sephadex G-50 Superfine resulted in an O-polysaccharide fraction (I) (PS-1) and two

oligosaccharide fractions (IIa and IIb). Sugar analysis using GLC of the alditol acetates derived after full acid hydrolysis of PS-1 revealed ascarylose (3,6-dideoxy-L-arabino-hexose), glucose, GlcN, and GalN. GLC of the acetylated methyl glycosides showed the presence of glucuronic acid (GlcA). Further studies showed that the O-polysaccharide did not contain glucose, which was evidently a component of the LPS core. The L configuration of the 3,6-dideoxyhexose and the D configuration of the other monosaccharides were determined by GLC of the acetylated (S)-2-octyl glycosides⁷ and were in agreement with the glycosylation effects on ¹³C NMR chemical shifts.⁸ In addition to the monosaccharides, L-alanine was identified by GLC of the acetylated ester with (+)-2-octanol.

The ¹³C NMR spectrum of PS-1 (Fig. 1, top) showed a structural heterogeneity, likely owing to non-stoichiometric O-acetylation (there was a signal for an O-acetyl group at δ 21.9). Mild alkaline treatment of PS-1 resulted in an O-deacetylated polysaccharide (PS-2), which was still irregular (Fig. 1, bottom) owing to partial loss of ascarylose during mild acid degradation of the LPS (see below). In addition, the sample was contaminated with a



Note

^{*} Corresponding author. Tel.: +7 499 1376148; fax: +7 499 1355328.

E-mail address: yknirel@gmail.com (Y.A. Knirel).

 $^{^\}dagger$ Present address: Science Complex, University of Guelph, Guelph, Ontario N1G 2W1, Canada.



Figure 1. ¹³C NMR spectra of the O-polysaccharide (PS-1) (top) and O-deacetylated polysaccharide (PS-2) (bottom) from *P. alcalifaciens* O2. Arabic numerals refer to carbons in alanine and sugar residues denoted by letters as follows: A, Asc; Gl, GlcN; Ga, GalN; aG, α -GlcA; bG, β -GlcA. Signals for the peptidoglycan-like polysaccharide⁸ are marked with asterisk.

peptidoglycan-like polysaccharide reported earlier to be common for a number of *Providencia* serogroups.⁹ In an attempt to obtain a regular Asc-lacking polymer, PS-2 was subjected to partial acid hydrolysis with 0.1 M CF₃CO₂H, and the products were fractionated by GPC on TSK HW-40 (S) to give fractions I-V.

The ¹H and ¹³C NMR spectra of fractions I-V were assigned using 2D COSY, TOCSY, ROESY, ¹H, ¹³C HSQC, HSQC-TOCSY, and HMBC experiments, and the NMR chemical shifts for fractions I, IV, and V are tabulated in Table 1. Fraction V was identified as free ascarylose.

Fraction IV was a tetrasaccharide (TS) composed of one linked residue each of α -GlcpA, β -GlcpA, and β -GlcpN, a GalN residue at the reducing end, as well as one alanyl and one *N*-acetyl group. The ¹H, ¹³C HMBC spectrum of TS showed a cross-peak between C-1 (CO) of Ala and H-2 of GlcN at δ 172.7/3.81, thus demonstrating *N*-alanylglucosamine (GlcNAla); hence, GalN is N-acetylated. The HMBC spectrum also showed the following correlations between anomeric protons and linkage carbons and vice versa: α -GlcA H-1/GlcNAla C-4, GlcNAla H-1/ β -GlcA C-4, β -GlcA H-1/ α - and β -GalNAc C-3, α -GlcA C-1/GlcNAla H-4, GlcNAla C-1/ β -GlcA H-4, and β -GlcA C-1/ α - and β -GalNAc H-3. These data showed that TS is linear and has the structure shown in Chart 1, which was confirmed by low-field positions of the signals for linkage carbons (Table 1) and a ROESY experiment (data not shown).

The structure of TS was also corroborated by ESI MS; the negative ion mass spectrum showed the $[M-H]^-$ ion peak at m/z 804.2532 (calculated m/z 804.2528 for $C_{29}H_{46}N_3O_{23}^-$). Similar MS analysis showed that fraction III represented an octasaccharide consisting of two TS repeats ($[M-H]^-$: experimental m/z 1591.4994; calculated m/z 1591.5022 for $C_{58}H_{91}N_6O_{45}^-$). Fractions II and I were found to be mixtures of higher oligomers up to

hexamer and octamer with dominant dodecasaccharide and eicosasaccharide, respectively (data not shown).

As compared with the ¹³C NMR spectrum of TS, in the spectrum of the fraction I polysaccharide (PS-3) the signal for C-6 of GlcNAla shifted downfield from δ 61.8 to δ 69.0. In the ¹H, ¹³C HMBC spectrum of PS-3, this signal showed a correlation with H-1 of β -GalNAc, thus indicating the GalpNAc-(β 1 \rightarrow 6)-GlcpNAla linkage. These data suggested that the repeat of PS-3 corresponded to TS and had the structure shown in Chart 1.

Therefore, partial acid hydrolysis of PS-2 completely split off ascarylose, the terminal monosaccharide residue of a polysaccharide side chain, and selectively cleaved some GalNAc linkages in the main chain.

As compared with the NMR spectra of PS-3, the spectra of PS-2 showed additional signals for an ascarylose residue. A comparison with the ¹H and ¹³C NMR data of the free monosaccharide (Table 1) indicated that ascarylose occurs as the α -pyranoside. The site of attachment of Asc was inferred by a downfield displacement of the signal for C-4 of α -GlcA from δ 73.1 in PS-3 to δ 80.1 in PS-2 and the presence of a Asc C-1/ α -GlcA H-4 cross-peak at δ 100.9/ 3.62 in the ¹H,¹³C HMBC spectrum of PS-2. Therefore, Asc is attached to α -GlcA at position 4, and PS-2 has the structure shown in Chart 1. In addition to the signals for PS-2, the NMR spectra of fraction I showed signals for PS-3, which was evidently due to partial loss of ascarylose during mild acid degradation of the LPS.

A comparison of the ¹H, ¹³C HSQC spectra of PS-2 and PS-1 showed a partial displacement of the GlcNAla H-3/C-3 cross-peak from δ 3.74/74.3 in PS-2 to δ 5.19/76.2 in PS-1, which was evidently due to a deshielding effect of the O-acetyl group¹⁰ and indicated O-acetylation of GlcNAla at position 3 (Chart 1). This conclusion was confirmed by upfield displacements (β -effects of

Table 1

¹H and ¹³C NMR chemical shifts (δ , ppm) and ³J_{H,H} coupling constants (Hz)

$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Residue	C-1	C-2	C-3	C-4	C-5	C-6
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		H-1	H-2	H-3 (3equiv, 3ax)	H-4	H-5	H-6 (6a,6b)
O-Decerptined polysacchride (PS-2)3)-βGclpNAc-[-410.295.48.18.16.027.66.2.3-4)-βClepA-[1-4105.67.377.5.38.3.17.6.18.7.2-4,6)-βClepNAls-[1-410.315.6.27.4.38.0.47.4.868.9-4,6)-βClepNAls-[1-410.3.15.6.27.4.38.0.47.4.868.9-4,6)-βClepA-(1-410.27.6.17.7.23.6.24.1.27.5.47.5.4-4,5-QClepA-(1-410.0.96.8.93.4.66.8.17.1.518.0-Asc-lecting polysaccharide (PS-7)10.35.2.38.2.0.23.582.9.91.1.6-Asc-lecting polysaccharide (PS-7)4.6.73.8.17.5.37.7.37.6.16.2.3-4,6.9-βClepNAl-(1-410.3.05.2.37.7.96.0.17.7.37.7.1-4,6.9-βClepNAl-(1-410.25.6.27.4.98.0.17.7.27.6.1-4,6.9-βClepNAl-(1-410.3.05.6.27.4.98.0.17.7.27.6.1-4,6.9-βClepNAl-(1-410.3.25.7.37.7.78.0.17.7.27.6.17.7.2-4.6.9-βClepNAl-(1-410.2.37.3.07.7.17.6.17.7.27.6.17.7.2-4.6.9-βClepNAl-(1-410.2.37.3.07.7.17.6.17.7.27.6.17.7.2-4.6.9-βClepNAl-(1-410.2.37.3.07.7.17.6.17.7.27.6.17.7.2-4.6.9-βClepNAl-(1-410.2.3 <td></td> <td>$(J_{1,2})$</td> <td>(J_{2,3ax})</td> <td>(J_{2,3equiv}; J_{3equiv,4}; J_{3equiv,3ax})</td> <td>(J_{3ax,4})</td> <td>(J_{4,5})</td> <td>(J_{5,6})</td>		$(J_{1,2})$	(J _{2,3ax})	(J _{2,3equiv} ; J _{3equiv,4} ; J _{3equiv,3ax})	(J _{3ax,4})	(J _{4,5})	(J _{5,6})
	O-Deacetylated polysaccharide (PS-	2)					
4)-βGlepA-{1-4 105.6 7.7 7.5 8.1 7.6.8 17.5 o. 4.6)-βGlepA(1-4 103.1 56.2 7.4 8.0.4 7.4.8 68.9 4.6)-βGlepA(1-5 102.4 7.3.1 7.3.0 80.1 7.5.8 7.5.7.4.2.1 4.3-φ-GlepA(1-5 102.4 7.3.1 7.3.0 80.1 7.5.6 17.5.7 A-3-φ-GlepA(1-5 10.0.9 68.9 3.6.6 68.1 7.1.5 18.0 A-3-6-GlepA(1-5 100.9 68.9 3.6.6 68.1 7.1.5 18.0 A-Sep-GlepA(1-4 103.0 5.3 82.0 69.2 7.6.1 62.3 4.6)-β-α-GlepA(1-4 103.0 5.3 7.5.3 83.4 7.5.9 17.6.1 4.6)-β-α-GlepA(1-4 103.2 56.2 7.4.9 80.1 7.4.9 7.1.7 7.3.7 4.6)-β-α-GlepA(1-4 103.2 56.2 7.4.9 80.1 7.4.9 7.1.7 7.3.6 3.7.7 7.2.3 7.1.7 7.3.6	\rightarrow 3)- β -D-GalpNAc-(1 \rightarrow	102.9	52.4	81.8	69.2	76.1	62.3
		4.41	4.05	3.80	4.09	3.63	3.72, 3.79
4.6) 3.24 3.62 3.62 3.65 3.82 -4.6) 4.52 3.76 3.74 3.63 3.78 3.75, 4.21 -4.9) 5.18 3.67 3.73 3.62 4.12 -4.3) 100 68.9 34.6 68.1 71.5 18.0 -4.8cp/C1+ 100.9 68.9 34.6 68.1 71.5 18.0 -4.9 -0.6dpNAc(1-1 10.0 52.3 82.0 3.8 3.99 12.1 -4.9 -0.6dpNAc(1-1 10.5 73.8 75.3 83.4 3.75 176.1 -4.4) 10.5.6 73.8 75.3 3.61 3.22 3.74 4.10 3.61 3.72 -4.4) 10.2.3 3.75 3.77 3.63 3.22 3.74 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12 4.12<	\rightarrow 4)- β -D-GlcpA-(1 \rightarrow	105.6	73.7	75.3	83.1	76.8	175.0
		4.56	3.34	3.62	3.65	3.82	
-4)-2ClqA-(1-) 162 3.76 3.74 3.63 3.78 3.75, 4.21 -4)-2ClqA-(1-) 163 3.67 3.73 3.62 4.12 q-Ascp.(1-) 10.9 68.9 34.6 68.1 71.5 3.99 1.21 Asc-lacking polysaccharide (P5.3) - - - - - - - -3)-lpGlapMa-(1-1) 103.0 52.3 82.0 69.2 76.1 62.3 -4,0-p-GlcpA-(1-4) 103.0 52.3 82.0 69.2 76.1 62.3 -4,0-p-GlcpA-(1-4) 103.0 73.8 75.3 33.4 60.0 37.4 27.4 27.5 176.1 -4,0-p-GlcpA/(1-4) 103.0 37.6 77.4 30.0 36.0 36.0 37.2 177.4 27.4 22.7 -4,6-p-P-GlcpA/(1-4) 103.0 77.4 36.3 37.2 37.4 22.5 37.4 36.3 37.2 37.4 42.2 -4-p-GlcpA-(1-4) 103.6 <th< td=""><td>\rightarrow 4,6)-β-D-GlcpNAla-(1\rightarrow</td><td>103.1</td><td>56.2</td><td>74.3</td><td>80.4</td><td>74.8</td><td>68.9</td></th<>	\rightarrow 4,6)- β -D-GlcpNAla-(1 \rightarrow	103.1	56.2	74.3	80.4	74.8	68.9
4)-schcGpA-(1-)102,473,173,080,173,6175,75,83,673,7373,624,12q-Ascp-(1-)100.968,934,668,171,518,03,9068,934,668,171,518,0Asc-lacking polysaccharide (75-3)		4.52	3.76	3.74	3.63	3.78	3.75, 4.21
β.18 3.67 3.73 3.62 4.12 2-Ascp.(1-4) 109 68.9 34.6 68.1 71.5 18.0 Asc-lacking polysacharide (PS-3) 3.94 1.89, 2.02 3.58 3.99 1.21 Asc-lacking polysacharide (PS-3) 3.62 82.0 69.2 7.61 62.3 -4)-β-0-GlcpA-(1-4 103.0 5.23 82.0 69.2 7.61 62.3 -4)-β-0-GlcpA-(1-4 103.0 5.23 82.0 3.61 3.72 -4,6)-β-0-GlcpA-(1-4 103.0 7.53 7.61 3.72 1.76.1 -4,6)-β-0-GlcpA-(1-4 103.2 5.62 7.49 80.1 7.43 69.0 -4,6)-β-0-GlcpA-(1-4 10.2 7.62 7.42 3.66 3.60 3.60 3.60 3.60 -e-GlcpA-(1-4 10.5 7.6 7.8 7.61 69.8 7.1.6 62.5 -3)-β-0-GlcpA-(1-4 10.6 7.5 10.5 7.6 7.5 17.6 17.6 17.6	\rightarrow 4)- α -D-GlcpA-(1 \rightarrow	102.4	73.1	73.0	80.1	73.6	175.7
α-Ascp (1-4)100.966.934.666.171.518.0Asc-lacking polysaccharide (PS-3).4573.941.89, 2023.583.991.21-3)-β-σ-CalpNA-(1-4)103.052.382.069.276.162.3-4)-β-σ-CalpNA-(1-4)105.673.875.383.477.5176.1-4,6)-β-σ-ClcpNAla-(1-4)105.673.875.383.477.5176.1-4,6)-β-σ-ClcpNAla-(1-4)103.256.274.980.174.369.0-4,6)-β-σ-ClcpNAla-(1-4)102.377.63.633.723.74 4.22-α-GlcpA-(1-4)102.373.074.273.174.7177.4-3/-g-c-GlpNAc92.550.178.73.683.603.603.60-3/-g-c-GlpNAc96.453.681.760.871.662.5-3/-g-p-CalpNAc96.453.681.760.176.262.3-4)-β-p-GlcpA-(1-4)105.673.675.7176.274.2-4)-β-p-GlcpA-(1-4)105.673.675.7176.274.2-4)-β-p-GlcpA-(1-4)105.673.675.7176.275.275.916.8-4)-β-p-GlcpA-(1-4)105.673.675.775.975.961.877.675.275.9176.2-4)-β-p-GlcpA-(1-4)105.673.63.623.653.7074.275.275.961.877.675.275.9176.275.275.9176.2 </td <td></td> <td>5.18</td> <td>3.67</td> <td>3.73</td> <td>3.62</td> <td>4.12</td> <td></td>		5.18	3.67	3.73	3.62	4.12	
Asc-acking polyaccharide (PS-3) 4.57 3.94 1.89, 2.02 3.58 3.99 1.21 Asc-acking polyaccharide (PS-3)	α -Ascp-(1 \rightarrow	100.9	68.9	34.6	68.1	71.5	18.0
Asc-lacking polysaccharide (PS-3) 3 -10 52.3 82.0 69.2 76.1 62.3 4)-β-o-CigpA-(1-) 105.6 73.8 75.3 83.4 77.5 176.1 4.6)-β-o-CigpA-(1-) 105.6 73.8 75.3 83.4 77.5 176.1 4.6)-β-o-CigpA(1-) 103.2 56.2 74.9 80.1 74.3 69.0 -a-6(pA-(1-) 102.3 73.0 74.2 73.1 74.7 177.4 -a-6(pA-(1-) 102.3 73.0 74.2 73.1 74.7 177.4 -a-3(-cigpA-(1-) 102.3 73.0 74.2 73.1 74.7 177.4 -3/-α-CalpNAc 92.5 50.1 78.7 69.8 71.6 62.5 -3/-β-o-CigpA-(1-) 105.6 73.6 87.7 69.1 76.2 62.3 -3/-β-o-CigpA-(1-) 105.6 73.6 75.4 83.6 77.5 176.2 -3/-β-o-CigpA-(1-) 105.6 73.6 75.2 78.0		4.57	3.94	1.89, 2.02	3.58	3.99	1.21
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Asc-lacking polysaccharide (PS-3)						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\rightarrow 3$)- β - β	103.0	52.3	82.0	69.2	76.1	62.3
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	\rightarrow 5)-p-b-Galpinic-(1 \rightarrow	105.0	106	3 70	4 10	3 65	3 73 3 78
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$(A) = \beta = p = C lcn A = (1)$	105.6	73.8	75.3	93.4	77.5	176.1
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\rightarrow 4$)-p-b-Gicpii-(1 \rightarrow	105.0	2 22	3.60	3.61	3 72	170.1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	(4.6)-B-D-ClcnNAl2-(1)	103.2	56.2	74.9	S.01 80.1	743	69.0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	\rightarrow 4,0)-p-b-Gicpiù lia-(1 \rightarrow	105.2	3 75	3 77	3.63	3 72	374 422
$\begin{array}{cccccc} 1 & 5 \ dip(1)^{1-1} & 10.3 & 10.3 & 14.2 & 15.1 & 14.1 & 14.0 & 17.4 \\ & 5.17 & 3.64 & 3.68 & 3.50 & 3.99 & 17.4 \\ \hline Tetrasaccharide (TS) & 2.5 & 50.1 & 78.7 & 69.8 & 71.6 & 62.5 \\ & -3)-q5-c-GlpNAc & 92.5 & 50.1 & 78.7 & 69.8 & 17.4 & 10 & 3.72 \\ & -3)-q5-o-GlpNAc & 96.4 & 53.6 & 81.7 & 69.1 & 76.2 & 62.3 \\ & -4)-q5-o-GlcpA-(1 \rightarrow & 105.6, & 73.6, & 75.4 & 83.6 & 77.5 & 176.2 \\ & 105.4 & 73.7 & & & & & & & & & & & & & & & & & & &$	α_{-D} -ClcnA-(1 \rightarrow	102.3	73.0	74.2	73.1	74 7	177 4
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	a b-diepri-(1-)	5 17	3 64	3 68	3 50	3 00	177.4
Tetrasaccharide (TS) -3)-α-p-GalpNAc 92.5 50.1 78.7 69.8 71.6 62.5 -3)- α -p-GalpNAc 96.4 53.6 81.7 69.1 76.2 62.3 -3)- β -p-GalpNAc 96.4 53.6 81.7 69.1 76.2 62.3 -4)- β -p-GlcpA-(1 - 105.6, 73.6, 75.4 83.6 77.5 176.2 -4)- β -p-GlcpA-(1 - 105.6, 73.6, 75.4 83.6 77.5 176.2 -4)- β -p-GlcpA-(1 - 103.1 56.4 75.2 78.0 75.9 61.8 -4 - β -p-o-GlcpA-(1 - 103.1 56.4 75.2 78.0 75.9 61.8 -4 - β -p-o-GlcpA-(1 - 100.7 72.7 73.9 73.1 74.3 177.6 -3 -oc-GlcpA-(1 - 100.7 72.7 73.9 73.1 74.3 177.6 -3 -co-glcpA-(1 - 100.7 72.7 73.9 73.1 74.3 177.6 -3 -co-glcpA-(1 - 100.7 </td <td></td> <td>5.17</td> <td>5.04</td> <td>5.00</td> <td>5.50</td> <td>5.55</td> <td></td>		5.17	5.04	5.00	5.50	5.55	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Tetrasaccharide (TS)						
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	→3)-α-D-GalpNAc	92.5	50.1	78.7	69.8	71.6	62.5
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		5.20	4.27	3.98	4.17	4.10	3.72
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	→3)-β-D-GalpNAc	96.4	53.6	81.7	69.1	76.2	62.3
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		4.67	3.98	3.80	4.11	3.68	3.74
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	\rightarrow 4)- β -D-GlcpA-(1 \rightarrow	105.6,	73.6,	75.4	83.6	77.5	176.2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		105.4	73.7				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		4.56,	3.36	3.62	3.65,	3.70	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		4.50			3.68		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	\rightarrow 4)- β -D-GlcpNAla-(1 \rightarrow	103.1	56.4	75.2	78.0	75.9	61.8
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		4.54,	3.81	3.81	3.71	3.67	3.79, 3.93
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		4.53		72.0	TO 1	740	477.0
Ascarylose3.603.683.493.97Ascarylose α -Ascp93.9369.3134.1168.3570.9318.104.9583.9182.049, 1.8563.6103.8621.252(1.4)(3.2)(4.3; 4.3, 13.6)(11.1)(9.1)(6.3) β -Ascp95.8469.1938.0368.0877.1818.39 4.866 3.9342.201, 1.7063.5653.4821.276(1.1)(3.6)(4.3; 4.3; 13.9)(11.6)(9.3)(6.2) α -Ascf103.3076.4432.6683.1369.3119.39 5.270 4.2052.389, 1.8384.1923.9361.174 (<1) (n.d.)(6.4; 8.2; 14.0)(8.2)(5.5)(6.6) β -Ascf101.0172.2731.3681.9670.1919.03 5.209 4.2732.299, 1.8213.9503.8961.169 (44) (9.9)(74:69:12.3)(8.9)(n.d.)(6.4)	α -D-GICPA-(1 \rightarrow	100.7	72.7	73.9	73.1	74.3	177.6
Ascarylose α -Ascp93.9369.3134.1168.3570.9318.104.9583.9182.049, 1.8563.6103.8621.252(1.4)(3.2)(4.3; 4.3, 13.6)(11.1)(9.1)(6.3) β -Ascp95.8469.1938.0368.0877.1818.394.8663.9342.201, 1.7063.5653.4821.276(1.1)(3.6)(4.3; 4.3; 13.9)(11.6)(9.3)(6.2) α -Ascf103.3076.4432.6683.1369.3119.395.2704.2052.389, 1.8384.1923.9361.174 (<1) (n.d.)(6.4; 8.2; 14.0)(8.2)(5.5)(6.6) β -Ascf101.0172.2731.3681.9670.1919.03 β -Ascf(4.4)(9.9)(74: 6.9: 12.3)3.8503.8961.169		5.42	3.60	3.68	3.49	3.97	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Ascarylose						
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	α-Ascp	93.93	69.31	34.11	68.35	70.93	18.10
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		4.958	3.918	2.049, 1.856	3.610	3.862	1.252
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		(1.4)	(3.2)	(4.3; 4.3, 13.6)	(11.1)	(9.1)	(6.3)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	β-Ascp	95.84	69.19	38.03	68.08	77.18	18.39
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		4.866	3.934	2.201, 1.706	3.565	3.482	1.276
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		(1.1)	(3.6)	(4.3; 4.3; 13.9)	(11.6)	(9.3)	(6.2)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	a-Ascf	103.30	76.44	32.66	83.13	69.31	19.39
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		5.270	4.205	2.389, 1.838	4.192	3.936	1.174
β-Ascf 101.01 72.27 31.36 81.96 70.19 19.03 5.209 4.273 2.299, 1.821 3.950 3.896 1.169 (4.4) (9.9) (7.4: 6.9: 12.3) (8.9) (p.d.) (6.4)		(<1)	(n.d.)	(6.4; 8.2; 14.0)	(8.2)	(5.5)	(6.6)
5.209 4.273 2.299, 1.821 3.950 3.896 1.169 (4.4) (9.9) (7.4: 6.9: 12.3) (8.9) (n.d.) (6.4)	β-Ascf	101.01	72.27	31.36	81.96	70.19	19.03
(44) (99) $(74.69.123)$ (89) (nd) (64)		5.209	4.273	2.299, 1.821	3.950	3.896	1.169
(1.7) (3.5) $(1.7, 0.5, 12.5)$ (0.5) $(1.0.)$ (0.7)		(4.4)	(9.9)	(7.4; 6.9; 12.3)	(8.9)	(n.d.)	(6.4)

¹H NMR chemical shifts are shown in italics.

n.d., not determined.

Additional chemical shifts for the *N*-alanyl group are δ_c 17.7–18.0 (C-3), 50.9 (C-2), and 172.6–172.7 (C-1), δ_H 1.52–1.53 (H-3) and 4.04–4.05 (H-2); for the *N*-acetyl group δ_c 23.7–23.8 (Me) and 176.0 (CO), δ_H 2.04–2.05 in the polysaccharides; δ_c 23.3 and 23.5 (both Me), 176.0 and 176.1 (both CO), δ_H 2.01 in TS; for the *O*-acetyl group δ_c 21.9 (Me) and 174.7 (CO), δ_H 2.08 in PS-1.

$\begin{array}{c} \alpha \text{-Asc}p\text{-}(1 \rightarrow 4)\text{-}\alpha\text{-}D\text{-}GlcpA\text{-}(1 \rightarrow 4)\text{-}\\ \rightarrow 6)\text{-}\beta\text{-}D\text{-}GlcpNAla\text{-}(1 \rightarrow 4)\text{-}\beta\text{-}D\text{-}GlcpA\text{-}(1 \rightarrow 3)\text{-}\beta\text{-}D\text{-}GalpNAc\text{-}(1 \rightarrow 6)\text{-}\\ OAc\text{-}3)^{\bot} \end{array}$	PS-1		
α -Ascp-(1 \rightarrow 4)- α -D-GlcpA-(1 \rightarrow 4) \rightarrow 6)- β -D-GlcpNAla-(1 \rightarrow 4)- β -D-GlcpA-(1 \rightarrow 3)- β -D-GalpNAc-(1 \rightarrow	PS-2		
$ \alpha\text{-D-Glc}pA-(1\rightarrow 4)_{\uparrow} $ $ \rightarrow 6)-\beta\text{-D-Gl}cpNAla-(1\rightarrow 4)-\beta\text{-D-Gl}cpA-(1\rightarrow 3)-\beta\text{-D-Gal}pNAc-(1\rightarrow 4)-\beta\text{-D-Gal}pNAc-(1\rightarrow 4)-\beta\text{-D-Gal}pNA-(1\rightarrow 4)-\beta\text{-D-Gal}pNA-(1\rightarrow 4)-\beta\text{-D-Gal}pNA-(1\rightarrow 4)-\beta\text{-D-Gal}pNA-(1\rightarrow 4)-\beta\text{-D-Gal}pNA-(1\rightarrow 4)-\beta\text{-D-Gal}pNA-(1\rightarrow 4)-\beta\text{-D-Gal}pNA-(1\rightarrow $			
$ \alpha \text{-D-Glc}pA-(1\rightarrow 4)-\beta \text{-D-Glc}pNAla-(1\rightarrow 4)-\beta \text{-D-Glc}pA-(1\rightarrow 3)-\text{D-GalNAc} $			

Chart 1. Structures of the O-polysaccharide (PS-1), O-deacetylated polysaccharide (PS-2), Asc-lacking polysaccharide (PS-3), and tetrasaccharide (TS) from *P. alcalifaciens* 02. In PS-1 and PS-2, ascarylose is present in a non-stoichiometric amount owing to its partial cleavage during mild acid degradation of the LPS. The degree of O-acetylation in PS-1 is ~60%.



Figure 2. Parts of charge-deconvoluted negative ion ESI mass spectra of fractions IIa (bottom) and IIb (top) isolated from the degraded LPS. Shown m/z values refer to [M–H]⁻ ions.

O-acetylation⁹) of the signals for the neighboring carbons C-2 and C-4 from δ 56.2 and 80.4 in PS-2 to δ 55.3 and 76.3 in PS-1, respectively. As judged by the ratio of integral intensities of the signals for OAc and NAc groups in the ¹H NMR spectra of PS-1, the degree of O-acetylation was ~60%.

Therefore, the O-polysaccharide of P. alcalifaciens O2 has the oligosaccharide repeat (O-unit) with the structure shown in Chart 1. This structure was confirmed by negative ion ESI MS analysis of fractions IIa and IIb isolated from the degraded LPS. The charge-deconvoluted spectrum of IIb (Fig. 2, top) showed the $[M-H]^-$ ion peak at m/z 2199.5341 for a Hex₄GalA₁Hep₃Ara4N₁anhKdo₁ P_1PEtN_3 core oligosaccharide (calculated m/z 2199.5347 for $C_{70}H_{123}N_4O_{66}P_4^-$), which has been reported earlier in the LPS of P. alcalifaciens O19 and O21.¹¹ In the spectrum of IIa (Fig. 2, bottom), the major $[M-H]^-$ ion peak at m/z 3158.8583 belonged evidently to the core bearing one O-unit, the O-unit having thus the molecular mass of 959.3242 Da (calculated m/z 3158.8578 for $C_{107}H_{180}N_7O_{92}P_4^-$; calculated molecular mass 959.3230 Da for Asc₁GlcA₂GalNAc₁GlcNAla₁Ac₁-H₂O). Both mass spectra also showed ion peaks for compounds lacking one and two PEtN groups (Δm ca. 123 Da) and that of Ia for compounds lacking Asc and/or O-acetyl group (Δm ca. 130 and ca. 42 Da, respectively).

A peculiar feature of the O-polysaccharide of *P. alcalifaciens* O2 is the presence of ascarylose and N-(L-alanyl)-D-glucosamine. Ascarylose has been known as a component of a few other bacterial polysaccharides, including *Yersinia pseudotuberculosis* 5a^{12,13} and *Vibrio cholerae* O:3.¹⁴ To our knowledge, N-(L-alanyl)-D-glucosa-

mine has been hitherto reported only once as a component of the O-polysaccharide of *Proteus penneri* 25 (O69)¹⁵, a representative of a genus closely related to *Providencia*.

1. Experimental

1.1. Bacterial strain and isolation of the lipopolysaccharide

Providencia alcalifaciens O2:H2 strain 67002 obtained from the Hungarian National Collection of Medical Bacteria (National Institute of Hygiene, Budapest) was cultivated under aerobic conditions in tryptic soy broth supplemented with 0.6% yeast extract. The bacterial mass was harvested at the end of the logarithmic growth phase, centrifuged, washed with distilled water, and lyophilized.

LPS was isolated in a yield of ~6.2% of dry bacterial mass by phenol–water extraction⁶ followed by dialysis of the extract without layer separation and freed from insoluble contaminations by centrifugation. The resultant solution was treated with cold (4 °C) aq 50% CCl₃CO₂H; after centrifugation the supernatant was dialyzed against distilled water and freeze-dried.

1.2. Preparation of the O-polysaccharide

A portion of the LPS (445 mg) was heated with 2% HOAc (9 mL) for 2.5 h at 100 °C, a lipid precipitate was removed by centrifugation at 13,000g for 20 min. The carbohydrate-containing supernatant was fractionated on a column (60×2.5 cm) of Sephadex G-

50 Superfine in 0.05 M pyridinium acetate buffer pH 4.5 to give one polysaccharide (PS-1) and two oligosaccharide fractions in yields 20.6, 31.0, and 108.9 mg, respectively.

1.3. O-Deacetylation and partial acid hydrolysis

PS-1 was subjected to O-deacetylation with 12% aqueous ammonia (0.5 mL, 37 °C, 16 h). Ammonia was removed with a stream of nitrogen at 20 °C, and the residual solution was lyophilized to give O-deacetylated polysaccharide (PS-2).

PS-2 (18.4 mg) was hydrolyzed with 0.1 M CF₃CO₂H (1 mL) at 100 °C for 2 h. Following acid evaporation the residue was fractionated by GPC on a column (80 \times 1.6 cm) of TSK HW-40 (S) in 1% HOAc to give fractions I (PS-3), II, III, IV (TS), and V (Asc) in yields 3.3, 4.1, 3.6, 2.0, and 1.0 mg, respectively

1.4. Composition analysis

A PS-1 sample was subjected to hydrolysis with 0.5 M CF₃CO₂H (100 °C, 30 min) or 2 M CF₃CO₂H (120 °C, 2 h) followed by reduction with a solution of NaBH₄ (0.4 mL, 10 mg mL⁻¹) in 1 M NH₄OH (20 °C, 2 h), or to methanolysis (1 mL MeOH, 0.1 mL AcCl, 85 °C, 16 h). The products were acetylated with a 1:1 Ac₂O-pyridine mixture (100 °C, 1 h) and analyzed by GLC using a Maestro (Agilent) 7820 GC (Interlab, Russia) equipped with a HP-5 ms column and a temperature gradient of 7 °C min⁻¹ from 160 to 290 °C. For determination of the absolute configurations of the monosaccharides, a PS-1 sample was hydrolyzed with 2 M CF₃CO₂H (120 °C, 2 h) and N-acetylated (400 µL saturated NaHCO₃ solution, 60 µL Ac₂O, 0 °C, 1 h) or (for GlcA) subjected to methanolysis as above. The products were heated with (S)-2 octanol (100 μ L) in the presence of CF₃CO₂H (15 µL) at 120 °C for 16 h, acetylated, and analyzed by GLC as above. Tyvelose (3,6-dideoxy-D-arabino-hexose) derived from the O-polysaccharide of Yersinia pseudotuberculosis O4b¹⁶ was used for preparation of the authentic samples for identification of ascarylose by GLC of the acetylated alditols and (S)-2-octanol.

1.5. NMR spectroscopy

Samples were freeze-dried twice from a 99.9% D₂O soln and dissolved in 99.95% D₂O. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance II 600 MHz spectrometer (Germany) at 20 or 30 °C. Internal sodium 3-(trimethylsilyl)propanoate-2,2,3,3-*d*₄ ($\delta_{\rm H}$ 0; $\delta_{\rm C}$ -1.6) was used as a reference for calibration. 2D NMR spectra were obtained using standard Bruker software, and Bruker TopSpin 2.1 program was used to acquire and process the NMR data. A mixing time of 150 and 200 ms was used in TOCSY and ROESY experiments, respectively. A 60-ms delay was used for evolution of

long-range couplings to optimize the 2D 1 H, 13 C HMBC experiment for coupling constant $J_{H,C}$ 8 Hz.

1.6. Mass spectrometry

High-resolution ESI MS was performed in the negative ion mode using a maXis instrument (Bruker Daltonics). Oligosaccharide samples (ca. 50 ng μ L⁻¹) were dissolved in a 1:1 (v/v) water-acetonitrile mixture and injected with a syringe at a flow rate of 3 μ L min⁻¹. Capillary entrance voltage was set at 3 kV and shield voltage at -500 V. Nitrogen was used as the drying gas, and the interface temperature was set at 180 °C. Internal calibration was done with ESI Calibrant Solution (Agilent).

Acknowledgments

This work was supported by the Ministry of Science and Higher Education, Poland (core funding for statutory research activity, grant 1132 from the Department of Immunobiology of Bacteria, University of Lodz).

References

- Yoh, M.; Matsuyama, J.; Ohnishi, M.; Takagi, K.; Miyagi, H.; Mori, K.; Park, K.-S.; Ono, T.; Honda, T. J. Med. Microbiol. 2005, 54, 1077–1082.
- Ewing, W. H. In Identification of Enterobacteriaceae; Edwards, P. R., Ed.; Elsevier: New York, 1986; pp 443–459.
- 3. Ovchinnikova, O. G.; Rozalski, A.; Liu, B.; Knirel, Y. A. *Biochem. (Moscow)* 2013, 78, 798–817.
- Ovchinnikova, O. G.; Shashkov, A. S.; Chizhov, A. O.; Moryl, M.; Rozalski, A.; Knirel, Y. A. Carbohydr. Res. 2014, 290, 67–70.
- Ovchinnikova, O. G.; Shashkov, A. S.; Chizhov, A. O.; Moryl, M.; Rozalski, A.; Knirel, Y. A. Carbohydr. Res. 2014, 398, 72–76.
- 6. Westphal, O.; Jann, K. Methods Carbohydr. Chem. 1965, 5, 83–91.
- 7. Leontein, K.; Lönngren, J. Methods Carbohydr. Chem. 1993, 9, 87-89.
- 8. Shashkov, A. S.; Lipkind, G. M.; Knirel, Y. A.; Kochetkov, N. K. Magn. Reson. Chem.
- 1988, 26, 735–747.
 Ovchinnikova, O. G.; Liu, B.; Kocharova, N. A.; Shashkov, A. S.; Kondakova, A. N.; Siwinska, M.; Feng, L.; Rozalski, A.; Wang, L.; Knirel, Y. A. *Biochem. (Moscow)* 2012, 77, 609–615.
- Jansson, P.-E.; Kenne, L.; Schweda, E. J. Chem. Soc., Perkin Trans. 1 1987, 377– 383.
- Kondakova, A. N.; Vinogradov, E. V.; Lindner, B.; Kocharova, N. A.; Rozalski, A.; Knirel, Y. A. J. Carbohydr. Chem. 2006, 25, 499–520.
- Gorshkova, R. P.; Korchagina, N. I.; Ovodov, Y. S. Eur. J. Biochem. 1983, 131, 345– 347
- 13. Ovodov, Y. S.; Gorshkova, R. P. Khim. Prir. Soedin. 1988, 135-141.
- Chowdhury, T. A.; Jansson, P.-E.; Lindberg, B.; Lindberg, J.; Gustavsson, B.; Holme, T. Carbohydr. Res. 1991, 215, 303–314.
- Arbatsky, N. P.; Shashkov, A. S.; Widmalm, G.; Knirel, Y. A.; Zych, K.; Sidorczyk, Z. Carbohydr. Res. 1997, 298, 229–235.
- Kondakova, A. N.; Bystrova, O. V.; Shaikhutdinova, R. Z.; Ivanov, S. A.; Dentovskaya, S. V.; Shashkov, A. S.; Knirel, Y. A.; Anisimov, A. P. Carbohydr. Res. 2009, 344, 152–154.